Purpose of review Noncoding RNAs (ncRNAs), such as microRNAs (miRNAs) and long noncoding RNAs (lncRNAs) are becoming fundamentally important in the pathophysiology relating to injury-induced vascular remodelling. We highlight recent studies that demonstrate the involvement of ncRNAs in vein graft disease, in in-stent restenosis and in pulmonary arterial hypertension, with a particular focus on endothelial cell and vascular smooth muscle cell function. We also briefly discuss the emerging role of exosomal-derived ncRNAs and how this mechanism impacts on vascular function.
INTRODUCTION
Vascular remodelling after acute injury is a multifactorial pathological process that contributes to cardiovascular disease, including in-stent restenosis (ISR), pulmonary arterial hypertension (PAH), atherosclerosis, and others [1, 2] . The remodelling process involves structural changes of the vessel as a consequence of altered cell proliferation/growth, cell apoptosis/death, cell migration, and modulation of the production and degradation of extracellular matrix (ECM) [3, 4] . Both endothelial and smooth muscle cells are key mediators of the pathological response to acute vascular injury, driving the progressive remodelling process that characterizes neointimal formation [5, 6] . In addition, inflammatory activation of the vessel wall also contributes to vascular remodelling [7] . Endothelial injury, such as the endothelial denudation that arises after implantation of stents into coronary vessels, is an important early contributor to the initiation of vascular inflammation [8] . Following injury, growth factors and cytokines released from endothelial cells and inflammatory cells promote smooth muscle cell proliferation, migration, and extracellular matrix protein deposition [9, 10] . Although multiple studies over the last 2 decades have focused on delineating the molecular mechanisms that drive the remodelling response to vascular injury [11] [12] [13] , with the exemption of drug-eluting stents, there is currently a paucity in effective therapeutics, necessitating further research and innovative thinking around molecular mechanisms that might govern pathological responses.
According to recent transcriptome analyses, protein-coding genes actually account for only 1.5-2.0% of the human transcriptome. The transcriptional output of the larger portion of the transcriptome (i.e. $98%) consists of noncoding RNA
MICRORNA BIOGENESIS AND FUNCTION
miRNAs are a novel class of endogenous, small/short noncoding transcripts of 16-29 nt in length RNA that negatively regulate gene expression via degradation or translational inhibition of their target mRNAs. The biogenesis of miRNA is well reviewed in several highly cited publications [17] [18] [19] . miRNAs are regarded as essential regulators in physiology and pathophysiology of the cardiovascular system [20, 21] . They are becoming an intriguing target for therapeutic intervention for a number of reasons. First, a single miRNA can regulate several hundred target genes (including targets in the same or complimentary cellular pathways) making miRNAs potentially very powerful disease modifiers [22] . Second, several lines of evidence demonstrate that miRNAs are essential regulators of vascular smooth muscle cell (VSMC) development, differentiation, and contractile function offering a rich repertoire of disease-modifying therapeutics [23] . Finally, RNA therapeutics benefit from a great deal of prior translational research [e.g. small interfering RNA (siRNA) and exon skipping technology] that suggest RNA therapeutics might be attractive, albeit with specific challenges such as delivery, off-target effects, etc. [24] .
THE ROLE OF MICRORNAs IN PATHOLOGICAL VASCULAR REMODELLING
Neointimal formation is a hallmark of many vascular diseases. VSMCs are one of the major cellular components of the vessel wall and are implicitly involved in neointimal formation [25] . For example, (and aligned to our own research) in vein graft disease, VSMC proliferation and migration contributes to the increased vein graft medial thickening, neointimal formation, and superimposed atherosclerosis [26] . Similarly, the proliferation of VSMC in response to vascular injury following angioplasty and stent implantation leads to neointimal formation and restenosis [27] . Further, a key feature of PAH is pulmonary vascular remodelling and development of occlusive and plexiform intimal lesions in the small, distal pulmonary vessels [28] . In this section, we discuss recent findings on the regulation of pathological vascular remodelling by miRNAs. 42] . These data, while conflicting, highlight the complex role that miR-21 might play in vascular remodelling in the distal vasculature in the lung. Further studies are now required to identify the mechanisms underlying these divergent phenotypes, potentially by exposing miR-21 conditional knockout animals to different experimental PAH induction protocols, or by utilizing novel strategies to inhibit miR-21 in situ. The role of miR-21 in PAH has been extensively reviewed elsewhere [43] . In a translational context, manipulation of miR-21 in different preclinical disease models has shown positive therapeutic effects, although it would be important to develop strategies for localized targeting of the miR-21 inhibitors to the vessel wall, such as in the case of eluting stents. Interestingly, a chemically modified oligonucleotide antimiR-21 manufactured by Regulus Therapeutics (San Diego, California, USA) has entered phase 1 clinical trials for the treatment of Alport Syndrome, a disease of the glomerular basement membrane, where miR-21 inhibition is aimed at targeting abnormal renal function [44] .
In addition to miR-21, several other miRNAs have been shown to play critical roles in the pathological response to acute vascular injury. miRNAs have been shown to mediate the effects of many known regulators of vascular disease, such as PDGF, TGFb/BMP, and the interleukin family of inflammatory cytokines. For example, miR-146b-5p is necessary for PDGF-induced VSMC phenotype transition [45] . miRNAs that control vascular functions by affecting TGFb family signalling have been reviewed elsewhere [46] . miRNAs also play a central role in the modulation of vascular cell behaviour and function during disease pathogenesis, such as Let-7a and miR-221 in vein graft disease [47, 48] , the miR-143/145 cluster in ISR and PAH [49, 39, 50 && ] and miR-30c [51] , miR-322 [52] , miR-130a [53] in PAH. An overview of confirmed target genes for these miRNAs is shown in Table 1 .
In summary, many miRNAs are now known to be associated with the development of vascular remodelling processes in vivo and in vitro, whereas manipulation of several miRNAs have shown therapeutic efficacy in animal models of vascular disease. However, many facets of miR biology remain to be fully elucidated, including their precise mechanisms of action, cell selectivity in effect and the factors underlying their diverse effects. Moreover, as previously stated, there is currently a lack of effective pharmacological strategies for the direct targeting of miRNA in disease pathogenesis. Thus, much work remains to be done to fully understand, target, and therapeutically manipulate the biological roles of miRNAs in vascular disease.
LONG NONCODING RNA TRANSCRIPTION AND FUNCTION
lncRNAs, in common with mRNAs, are generally transcribed by RNA Polymerase II, and further spliced, 5 0 -capped (m7G), and 3 0 -polyadenylated [57] . The transcriptional regulation of lncRNA is well reviewed elsewhere [58] . lncRNA are, in general, expressed at relatively low levels and are far less well conserved than miRNA [59] [60] [61] . lncRNA can be classified into different subtypes based on their genomic location: sense lncRNAs, antisense lncRNAs, bidirectional lncRNAs, intronic lncRNAs, and intergenic lncRNAs [62] . lncRNAs have diverse molecular mechanisms of regulating gene expression through interactions with DNA, RNA, or protein, by acting as decoys, scaffolds, guides, or signalling molecules ( Fig. 1 ). In addition, lncRNAs can regulate gene expression post-transcriptionally, for example, by modulating splicing, mRNA translation and mRNA degradation, or by acting as miRNA sponges. There are several comprehensive reviews summarizing the functions and mechanisms of lncRNA [58, [63] [64] [65] [66] .
pathophysiology. Early studies identified antisense noncoding RNA in the INK4 locus (ANRIL), an lncRNA expressed in VSMC, which was able to regulate CDKN2A/B expression in aortic VSMC and attenuate proliferation in atherosclerosis [67] [68] [69] as well as modulate inflammatory responses in coronary artery disease [70] . lnc-Ang362, which hosts the miR-221 and miR-222 genes, was shown to be regulated by angiotensin II in VSMC, and was in turn able to modulate VSMC proliferation, vascular remodelling and neointimal hyperplasia in concert with miR-221 and miR-222 [54, 71, 72] . These studies showed that lncRNAs were involved in the control of cell proliferation, and could be regulated alongside proximal miRNAs in VSMCs. RNA-Seq analysis of human coronary artery SMC revealed a novel lncRNA, Smooth muscle and Endothelial cell-enriched migration/differentiation-associated long NonCoding RNA (SENCR), which is expressed in both VSMCs and endothelial cells. In VSMCs, knockdown of SENCR decreased the expression of myocardin and numerous smooth muscle contractile genes and increased a number of promigratory genes [namely Midkine (MDK) and Pleiotrophin (PTN)]. Inhibition of these two genes reversed the increased VSMC migration mediated by SENCR silencing, which suggested that the expression of these genes was partially regulated by SENCR in these cells. However, the functions of SENCR in endothelial cells were not reported in this study [73 & ]. Our group further revealed that SENCR induced the proliferation, migration, and angiogenesis of Human Umbilical Vein Endothelial Cells (HUVECs). In patient samples, SENCR expression was altered in vascular tissues and cells derived from patients with critical limb ischemia and premature coronary artery disease compared with healthy controls [74] . These two studies revealed that SENCR could modulate the behaviour of both SMC and endothelial cell, and exhibited altered expression patterns in vascular tissues and cells from vascular disease patients. However, the exact molecular targets and mechanisms of SENCR in pathological vascular remodelling remain to be determined.
Similar to SENCR, lincRNA-p21 is expressed in both VSMC and endothelial cell. In human VSMCs, lincRNA-p21 repressed cell proliferation and induced apoptosis in vitro. lincRNA-p21 also inhibited neointimal formation in carotid arteries and repressed proliferation and induced apoptosis in carotid artery injury model in vivo. The authors further confirmed the expression level of lincRNAp21 was decreased in patients with coronary heart disease [55 && ]. In mouse endothelial cell, lincRNA-p21-induced cell apoptosis and cell cycle progression. In addition, lincRNA-p21 inhibited cell proliferation through binding miR-130b [75] . Unlike many lncRNAs, lincRNA-p21 contains a very highly conserved 780 nt length 5 0 region in mammals, which provided the possibility of using an in-vivo animal model to study the role of this lncRNA [76] . These data identified lincRNAp21 as a key regulator of cell proliferation and apoptosis in vascular cells, which are primary contributors to vascular remodelling. Consistent with the human in-vitro data, knockdown of lincRNAp21 resulted in dramatic neointimal hyperplasia in a mouse model of carotid artery injury, which indicated that lincRNA-p21 could serve as a therapeutic target to treat vascular remodelling diseases [55 && ]. Using RNA-Seq, we recently defined a novel smooth muscle-specific lncRNA SMILR, which could be induced by IL-1a and PDGF in human saphenous vein (HSV) smooth muscle cells. Knockdown of SMILR markedly reduced HSV smooth muscle cell proliferation, likely through regulation of the HAS2 gene, located proximal to the genetic locus for SMILR. In human samples, SMILR expression increased in unstable atherosclerotic plaques and plasma from patients with high plasma C-reactive protein [77 && ]. These data suggested that inhibiting SMILR expression could be a potential target for treating vascular diseases characterized by VSMC proliferation.
In the context of endothelial cells, studies have shown that the lncRNA metastasis associated lung adenocarcinoma transcript 1 (MALAT1) could regulate retinal vessel remodelling by affecting retinal endothelial cell proliferation, migration, and tube formation, as genetic ablation of MALAT1 inhibited the proliferation of endothelial cell and reduced neonatal retina vascularization in vivo [78, 79 && ]. In human aortic endothelial cell, knockdown of the lncRNA H19-reduced cell proliferation and activated p21/CDKN1A, increasing apoptosis, decreasing angiogenesis, and diminishing the number of cells in G0/G1 and S phases in cell cycle [80] . These two lncRNAs that are highly expressed in endothelial cells showed multifunctional features both in vivo and in vitro. Endothelial cell lncRNAs have been also reviewed elsewhere [81] [82] [83] . An overview of target genes/miRNAs of these lncRNAs is given in Table 1 . In summary, there are few lncRNAs that have been studied in depth in the context of vascular disease, with most studies simply reporting the dysregulation of vascular cell function after manipulation of the lncRNAs. The direct targets and mechanisms of many lncRNA remain largely unknown, so urgent attention is needed in this context, particularly relating to their mechanism of action. Unfortunately, the low conservation of many lncRNAs restricts the availability of in-vivo disease models, which is a significant impediment to translation of lncRNA therapeutics to the clinical arena. Therefore, much more work is required to fully explore the role of lncRNAs in the pathophysiological processes driving vascular disease, sometimes using innovative models with human cells and tissues.
VASCULAR CELL-TO-CELL COMMUNICATION THROUGH MICRORNAs
Cell-to-cell communications can be mediated by extracellular vesicles, exosomes, apoptotic bodies, microparticles, and tunnelling nanotubes [84, 85] . Exosomes are 40-100 nm in size and represent a specific subtype of secreted membrane vesicles formed through the fusion of multivesicular endosomes with the plasma membrane [86] . Exosomes are released by many types of cell, and have been identified in most body fluids, including plasma, urine, saliva, cerebrospinal, amniotic and synovial fluids. Exosomes are now known to carry a wide array of molecules including: proteins, DNAs, mRNAs, miRNAs, and lncRNAs, depending on a variety of factors, including the cell type from which the exosome originates the state of health of the host and extracellular stimuli [87] . Exosomes can be taken up by neighbouring or distant cells and can be functional in the recipient cells by fusion with the plasma membrane, via receptor-mediated uptake or by internalization via endocytosis or macropinocytosis [88] . As the discovery of miRNA in exosomes, a number of studies have focused on the identification and function of exosomal miRNAs in cancer [89] and cardiovascular diseases [90] [91] [92] [93] [94] . Interestingly, cancer cell-derived exosomes contain key components of miRNA biogenesis, including the proteins RNA-induced Silencing Complex (RISC), argonaute-2 (AGO2), Dicer, and TAR RNA-binding protein (TRBP), which displayed cell-independent capacity to process precursor miRNAs into mature miRNAs [95] . Here, we focus on the role of exosomal miRNAs in vascular cells.
An early study showing the importance of exosomal miRNAs in vascular cells evaluated exosomal miR-143/145 in atherosclerosis. This study showed that miR-143/145 can affect vascular cell function following exosomal transport, via cell-to-cell communication. Kruppel like factor 2 (KLF2) or shear-stimulated HUVECs secreted miR-143/145 enriched exosomes, which could be taken up by VSMCs to derepress the targets genes of miR-143/ 145 [such as EST domain-containing protein Elk-1 (ELK1), Kruppel like factor 4 (KLF4), matrix metallopeptidase 3 (MMP3), slingshot protein phosphatase 2 (SSH2)] and induce an atheroprotective SMC phenotype both in vitro and in vivo [96] . In the pulmonary vasculature, we recently found that exosomal miR-143 derived from pulmonary artery smooth muscle cells can be transferred to pulmonary artery endothelial cells exerting promigratory and proangiogenic effects [50 && ]. Apart from exosome-mediated transfer, TGFb triggered miR-143/145 transfer to endothelial cells from VSMCs via tunnelling nanotubes. Overexpression of miR-143/145 in endothelial cells had antiangiogenic effects and reduced endothelial cell proliferation by directly targeting hexokinase 2 (HK2) and integrin beta-8 (ITGb8), separately [97 && ]. These data demonstrated the vital role of miR-143/145 in vascular cell proliferation, migration, and angiogenesis. Other endothelial cell secreted miRNAs, including miR-126 that could be taken by VSMCs via Ago2-facilitated miRNA transmission [98] , miR-26a [99 & ], and miR-214 [100] . The cell-to-cell communication between vascular cells by miRNAs is summarized in Fig. 2 . This is a relatively new field and there is much to discover about miRNA regulation and function through secretion and cell-to-cell communication.
Exosomal lncRNAs have been found in several cancer cells and patient's plasma. These include lncRNA HOX transcript antisense RNA (HOTAIR) [101] , H19 [102] , Long intergenic Non-coding RNA, Regulator Of Reprogramming (lincRNA ROR) [103] , linc-VLDL receptor (VLDLR) [104] , lncRNA transcript uc.339 (TUC339) [105] , lncRNA-p21 [106] , and other lncRNAs [107] . However, there is no report about exosomal lncRNAs secreted by the vascular cells. Recently, our group demonstrated that smooth muscle enriched long noncoding RNA (SMILR) was secreted into the cell culture media but was located in a nonexosomal or microparticle fraction [77 && ]. More studies should be performed to investigate the secretory pathways utilized by this lncRNA, the function of the secreted lncRNA molecules and the compartment or fraction that the lncRNA is located within. More generally, it would be important to identify whether cell-cell communication mediated by exosomal or microparticle lncRNAs plays a role in regulating
THERAPEUTIC PROSPECTIVE OF NONCODING RNAs
The translation of ncRNAs from bench to bedside has received considerable attention in recent years. In general, the therapeutic approaches involve the inhibition or overexpression of ncRNAs. Several approaches to manipulate ncRNAs are currently in use preclinically, including miRNA antagonists, miRNA mimics, antisense oligonucleotide, and siRNA. The first antimiRNA (Miravirsen) to enter clinical trials is a locked nucleic acid-modified DNA phosphorothioate antisense oligonucleotide targeting miR-122, which sequesters mature miR-122 to treat patients with hepatitis C. Miravirsen is currently in phase 2 clinical trials [108, 109] . miR-RX34 (MRX34), a double-stranded miR-34 RNA mimic encapsulated in a liposomal nanoparticle formulation, is the first miRNA mimic to enter phase 1 clinical trials [110] . Several antimiRNA/mimic therapeutics targeting miRNAs are currently under development, including Let-7, miR-21, miR-208, miR-195, miR-221, miR-29, miR-155, miR-10b, and miR-103/107. Four of these miRNA-based therapeutic drugs have entered into phase 1 clinical trials [111] [112] [113] [114] 115 & ]. Despite intensive studies of miRNAs in vascular disease, there is no miRNA-based therapeutics entering clinical trials at present in this area. One of the obstacles impeding development of miRNA-based therapeutics is low delivery efficacy to the vasculature and the likely need for repeated delivery. There are several strategies to deal with miRNA-based therapeutic challenges, which are summarized and discussed in this review [115 & ]. However, despite the obstacles, pharmacological manipulation of disease-associated miRNAs shows promising therapeutic potential in animal disease models. With more and intensive studies of miRNAs in-vitro and in-vivo preclinical models and human patients, the application of miRNA-based therapeutics in the clinic can become a reality. For lncRNAs, there are also several obstacles facing the development of lncRNA-based therapeutics. First, the functions and mechanisms used by lncRNAs are much more complex and diversified than miRNAs [116] . In spite of recent studies, lncRNAs are still largely an 'unknown' with regard to their cellular functions and molecular mechanisms. Second, the majority of lncRNAs that localize to the nucleus are thought to act as epigenetic regulators [117] . This feature makes it hard to target lncRNAs using siRNA, which is a potential therapeutic strategy. Third, most lncRNAs lack conservation between species, which restricts the utility of preclinical disease models. One possible strategy to overcome these issues is to identify the direct targets of disease-associated lncRNAs and use preclinical disease models to assess the therapeutic role of these targets in disease pathogenesis and/or use innovative human-based model systems ex vivo and in vitro.
CONCLUSION
Recent studies have dramatically improved our understanding of the multifaceted roles that ncRNAs play in pathological vascular remodelling. The expressions of several miRNAs have been shown to be dysregulated in various animal disease models as well as in patient samples, whereas novel direct targets of these disease-associated miRNAs have been validated. Manipulation of these miRNAs in preclinical animal models has shown therapeutic benefit. However, there are still some less-understood aspects of miRNA biology that require further study, for example the role(s) of miRNA passenger strands (which in some cases have been shown to be functional), in-vivo targeting (as most targeted studies of miRNAs are carried out in vitro) and miRNAmiRNA or miRNA-lncRNA interactions. Compared with miRNAs, only a few lncRNAs have been investigated in depth in vascular disease. The cellular function and biological mechanisms utilized by these lncRNAs still requires further exploration. Taken together, the evidence summarized in this review reveals that targeting ncRNAs may be a promising therapeutic strategy for the treatment of diseases characterized by vascular remodelling. 
